Ozmosi | Daporinad Drug Profile

Product Description

Mechanisms of Action: NAMPT Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TopoTarget A/S
Company Location:
Company Founding Year: 2000
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
2005-006157-24	APO866 for CTCL	P2	Completed	Mycosis Fungoides\|Lymphoma, B-Cell\|T-Cell Cutaneous Lymphoma\|Lymphoma, Non-Hodgkin	2011-09-22	2025-05-23	Treatments
NCT00431912	AP3001	P2	Completed	T-Cell Cutaneous Lymphoma\|T-Cell Peripheral Lymphoma	2011-01-01	2023-12-14	Primary Endpoints
2006-000910-19	2006-000910-19	P2	Completed	Melanoma	2009-03-24	2022-03-12	Treatments
2006-002850-31	2006-002850-31	P2	Completed	Chronic Lymphoid Leukemia	2008-02-02	2022-03-12	Treatments
NCT00432107	AP3003	P2	Completed	Melanoma	2008-02-01	2023-12-14	Primary Endpoints\|Treatments
NCT00435084	AP3005	P2	Completed	Chronic Lymphoid Leukemia\|Lymphocytic Chronic B-Cell Leukemia	2008-02-01	2023-12-14	Primary Endpoints

Recent News Events

Date	Type	Title
05/09/2024	PubMed	Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
04/15/2024	PubMed	Palmatine Attenuated Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting M1 Phenotype Macrophage Polarization via NAMPT/TLR2/CCR1 Signaling.
03/31/2024	PubMed	Effect of NAMPT on the proliferation and apoptosis in odontoblast-like MDPC-23 cell.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Daporinad

Alternative Names: daporinad, apo866, fk866 Clinical Status: Inactive Latest Update: 2024-05-09 Latest Update Note: PubMed Publication